Complementary, alternative medicine integration into clinical cancer care needs to be individualized
the ONA take:
Researchers at the Abramson Cancer Center at the University of Pennsylvania’s Perelman School of Medicine conducted a survey-based study to determine what drives the use of complementary and alternative medicine (CAM) among cancer patients.
The researchers surveyed 969 patients from the institution’s thoracic, breast, and gastrointestinal medical oncology clinics.
The findings reveal that expectation of therapeutic benefits, patient-perceived barriers regarding cost and access, and opinions of patients’ physician and family members predict patients’ use of CAM.
These beliefs and attitudes varied by key socio-demographic factors such as sex, race, and education.
Proven effectiveness of CAM practices such as yoga and acupuncture continue to support the practice of integrative oncology, which merges complementary and alternative medicine with conventional medicine to improve patient outsomes.
The researchers conclude that patient education on CAM practices should be tailored to the individual patient when integrating them into clinical care.
A study to determine what drives the use of complementary and alternative medicine among cancer patients.
- Immunotherapy May Benefit Some Patients with Papillary Thyroid Carcinoma
- New Study Questions Standard Dosage for Treating Metastatic Non-Small Cell Lung Cancer
- Clinical Trials May Benefit Oncology Patients
- Breast Cancer Overdiagnosis Also a Result of Screening Mammography Programs
- Prostate-specific PET and CT Imaging Improves Detection of Disease and Patient Care
- Survivorship Care Plans: Providing A Blueprint for Health Care After Cancer
- Multifaceted Role of the Nurse Navigator Includes Palliative, Supportive Care
- Cancer Recurrence Fear Reduced by Novel Psychological Intervention
- Patient Navigators Found to Boost Lung Cancer Screening Rates
- Immune Thrombocytopenia (Fact Sheet)
- Novel 3D Marker Reduces Radiation, Improves Cosmesis in Breast Conserving Surgery
- Rates at Some Milestones May Indicate Clinical Trial Results for Immunotherapeutics
- Cancer Risks for BRCA1/2 Mutation Carriers Determined by Age, Family History, Mutation Location
- Long-Term Use of TPO Receptor Agonist Safe in CLL-Associated Immune Thrombocytopenia
- Savolitinib Active, Tolerable in Subset of Advanced Papillary Renal Cell Cancer
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|